|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
over 10 countries
|
|
gptkbp:age
|
18 years and older
|
|
gptkbp:alsoKnownAs
|
gptkb:CanSino_COVID-19_vaccine
gptkb:Convidecia
|
|
gptkbp:antigen
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:approvedBy
|
February 2021
|
|
gptkbp:boosterUse
|
approved in some countries
|
|
gptkbp:category
|
gptkb:COVID-19_pandemic_in_China
Chinese inventions
Viral vector vaccines
|
|
gptkbp:clinicalTrialPhase
|
NCT04526990
|
|
gptkbp:countryOfOrigin
|
gptkb:China
|
|
gptkbp:developer
|
gptkb:CanSino_Biologics
gptkb:Beijing_Institute_of_Biotechnology
|
|
gptkbp:dosingRegimen
|
single dose
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
~90%
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~65%
|
|
gptkbp:emergencyServices
|
gptkb:Argentina
gptkb:Chile
gptkb:China
gptkb:Ecuador
gptkb:Hungary
gptkb:Indonesia
gptkb:Malaysia
gptkb:Mexico
gptkb:Pakistan
gptkb:Uzbekistan
|
|
gptkbp:form
|
0.5 mL
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ad5-nCoV
|
|
gptkbp:manufacturer
|
gptkb:Instituto_Butantan
Biomanguinhos/Fiocruz
SAVAL
Walvax Biotechnology
|
|
gptkbp:phase3TrialLocation
|
gptkb:Argentina
gptkb:Chile
gptkb:Mexico
gptkb:Pakistan
gptkb:Russia
gptkb:Saudi_Arabia
|
|
gptkbp:publishedIn
|
gptkb:The_Lancet
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
injection site pain
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
recombinant adenovirus vector
|
|
gptkbp:vaccineType
|
viral vector vaccine
|
|
gptkbp:vectorFor
|
gptkb:adenovirus_type_5
|
|
gptkbp:WHOStatus
|
under assessment
|
|
gptkbp:bfsParent
|
gptkb:CanSino_COVID-19_vaccine
|
|
gptkbp:bfsLayer
|
5
|